Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06972992 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
A Phase 1 study of Chronic Weight Management, sponsored by Ascletis Pharma (China) Co., Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06972992: Completed Phase 1 study of Chronic Weight Management, sponsored by Ascletis Pharma (China) Co., Limited.
NCT06972992 is a Phase 1 study of Chronic Weight Management that has completed, run by Ascletis Pharma (China) Co., Limited. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06972992, a Phase 1 study of Chronic Weight Management, has completed, sponsored by Ascletis Pharma (China) Co., Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.
Primary Outcome
Evaluate the incidence of Serious Adverse Events (SAEs) and Adverse Events (AEs)
Conditions Studied
Interventions
- DRUG ASC47 +Semaglutide
- DRUG Placebo+Semaglutide
Study Locations (1)
Texas
- Ascletis Clinical Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-04-18 |
| Est. Completion | 2025-09-22 |
| Phase | Phase 1 |
What the finished NCT06972992 record still lists
NCT06972992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Chronic Weight Management appearing as the primary indexed condition, and to 2 interventions - of which ASC47 +Semaglutide is the first listed.
NCT06972992 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06972992 about?
NCT06972992 is a clinical study titled "A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide". This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.
What is the current status of trial NCT06972992?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2025-04-18. Estimated completion is 2025-09-22.
What conditions does trial NCT06972992 study?
This clinical trial studies the following conditions: Chronic Weight Management.
What interventions are being tested in trial NCT06972992?
The interventions under investigation include: ASC47 +Semaglutide (DRUG), Placebo+Semaglutide (DRUG).
Who is sponsoring clinical trial NCT06972992?
This trial is sponsored by Ascletis Pharma (China) Co., Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06972992 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Weight Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06972992's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
ACTIVE NOT RECRUITING · Phase 1
-
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI